Skip to main content
Clinical Trials/NCT03524716
NCT03524716
Completed
Not Applicable

Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II (Smart Pace II)

University of California, San Francisco1 site in 1 country44 target enrollmentMarch 6, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
University of California, San Francisco
Enrollment
44
Locations
1
Primary Endpoint
Fitbit wear time
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

There is a critical need for physical activity interventions in colorectal cancer (CRC). The investigators have developed a digital health physical activity intervention, Smart Pace, which includes a wearable tracker (Fitbit) and text messaging and aims to have patients build up to 150 min/wk of moderate activity. In this study, the investigators propose to expand and improve Smart Pace, including: 1) enrolling patients during chemotherapy; 2) tailoring text messages to individual preferences and treatment timing; and 3) adding resources to support home-based exercise. The study is a 12-week pilot randomized controlled trial (RCT) to evaluate the feasibility of this novel digital health physical activity intervention among 48 CRC patients on chemotherapy. The specific aims are to: 1) Determine the feasibility of the intervention via adherence and attrition, and determine the acceptability of the intervention via questionnaires and semi-structured interviews . 2) Estimate the effect of the intervention vs. usual care on physical activity, QOL, and symptoms at 12-weeks . And 3) Explore the impact of the intervention vs. usual care on fitness, weight, waist circumference, and blood pressure at 12-weeks.

Registry
clinicaltrials.gov
Start Date
March 6, 2018
End Date
August 21, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with colon or rectal adenocarcinoma
  • Expected to receive at least 12 weeks of chemotherapy
  • Able to speak and read English
  • Access to a mobile phone with Internet and text messaging capabilities
  • ≥4 weeks since last major surgery and fully recovered
  • ≥18 years old
  • Physician consent to participate in unsupervised moderate intensity physical activity
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Exclusion Criteria

  • Engaging in 150 minutes/week or more of moderate physical activity, 75 minutes/week or more of vigorous physical activity, or an equivalent combination
  • Hypertension that is not well-controlled (≥160/90) on anti-hypertensive therapy
  • Any contraindications to exercise, including, but not limited to: brain metastases; current congestive heart failure (New York Heart Association Class II, III or IV); serious or nonhealing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy ≥grade 3; advanced Chronic Obstructive Pulmonary Disease (COPD) on oxygen
  • Serious cardiovascular event within 6 months including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI)
  • Has been told by a doctor that he/she has a heart condition and recommended to only engage in medically supervised activity

Outcomes

Primary Outcomes

Fitbit wear time

Time Frame: up to 12 weeks from study start

Number of study days Fitbit is worn

Acceptability of the intervention

Time Frame: At 12 weeks from study start

Acceptability will be assessed with an investigator created questionnaire among participants in the intervention arm.

Text message response rate

Time Frame: up to 12 weeks from study start

Secondary Outcomes

  • Objective physical activity(At 0 weeks and 12 weeks from study start)
  • Fatigue(At 0 and 12 weeks from study start)
  • Cardiorespiratory fitness(At 0 and 12 weeks from study start)
  • Anthropometrics, Waist circumference(At 0 and 12 weeks from study start)
  • Anthropometrics, Body weight(At 0 and 12 weeks from study start)
  • Sleep quality(At 0 and 12 weeks from study start)
  • Health-related quality of life in cancer patients(At 0 and 12 weeks from study start)
  • Health-related quality of life in colorectal cancer patients(At 0 and 12 weeks from study start)
  • Neuropathy(At 0 and 12 weeks from study start)
  • Anxiety(At 0 and 12 weeks from study start)
  • Depression(At 0 and 12 weeks from study start)
  • Leisure-time physical activity(At 0 and 12 weeks from study start)
  • Perceived barriers to physical activity(At 0 and 12 weeks from study start)
  • Exercise Confidence(At 0 and 12 weeks from study start)
  • Social support(At 0 and 12 weeks from study start)

Study Sites (1)

Loading locations...

Similar Trials